Months 3, 5, 7: Technical progress reports detailing technical progress made, tasks accomplished, major risks/mitigations, a technical plan for the remainder of Phase II (while this will normally report progress against the plan detailed in the proposal or presented at the Kickoff briefing, it is understood that scientific discoveries, competition, and regulatory changes may all have impacts on the planned work and DARPA must be made aware of any revisions that result), planned activities, trip summaries, and any potential issues or problem areas that require the attention of the DARPA PM
Patients on tirzepatide who also take glutathione for antioxidant support (common in NAFLD or metabolic syndrome) can continue both
However, clinical data specifically evaluating their concurrent use are lacking, so theoretical considerations and individual patient factors must guide decision-making with healthcare provider input
Experimental investigations have examined the relationship between NNMT inhibition and regulatory pathways involving nicotinamide turnover, methylation dynamics, transcriptional control mechanisms, and downstream signal transduction processes
